The challenge of addressing CNS changes with ERT is also seen with mucopolysaccharidosis II, an LSD for which IV idursulfase improves somatic signs and symptoms of the disease, but does not cross the blood–brain barrier in therapeutic quantities and cannot mitigate CNS aspects of the disease.17 This evidence concerns the gene IDS and mucopolysaccharidosis type 2.